Good morning :)
$
₹
Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd

SCNI

NASDAQ
Asset Logo

Scinai Immunotherapeutics Ltd

SCNI

NASDAQ
$1.511.55% (-0.02)
$
₹
$1.511.55% (-0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $1.2M the stock is ranked 6186

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

0.06
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.18
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$28.07
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-174.78%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Analysts expect a +45952.63% price upside over the next year

Current Price$1.51
Target Price$700

Company Profile

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Peers

Peers

Micron Technology Inc
MU
Micron Technology Inc
P/E Ratio
20.86
20.86
1Y Return
483.76%
483.76%
Buy Reco %
83.78
83.78
ASML Holding NV ADR
ASML
ASML Holding NV ADR
P/E Ratio
53.46
53.46
1Y Return
82.72%
82.72%
Buy Reco %
86.36
86.36
Lam Research Corp
LRCX
Lam Research Corp
P/E Ratio
47.48
47.48
1Y Return
123.92%
123.92%
Buy Reco %
72.72
72.72
Applied Materials Inc
AMAT
Applied Materials Inc
P/E Ratio
36.60
36.60
1Y Return
139.82%
139.82%
Buy Reco %
79.48
79.48
KLA Corporation
KLAC
KLA Corporation
P/E Ratio
46.07
46.07
1Y Return
68.95%
68.95%
Buy Reco %
63.33
63.33

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Scinai Immunotherapeutics Ltd 0.060.18-
Micron Technology Inc20.8610.930.14
ASML Holding NV ADR53.4625.691.51

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.2
-2
0.4
3.5
0.4
-2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.280.160.200.580.380.26-0.480.46
Net Income-2.15-2.3210.45-2.23-1.55-2.06-2.08-3.56-2.03
Net Profit Margin--817.60%6223.21%-1082.52%-265.69%-534.79%-775.65%-731.49%-435.43%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Scinai Immunotherapeutics Ltd (SCNI) share price today is $1.51 as of September 17, 2026 at 1:30 AM IST. The stock touched a day high of $1.55 and a day low of $1.44.

  2. Scinai Immunotherapeutics Ltd stock trades on NASDAQ under the ticker symbol SCNI.

  3. Scinai Immunotherapeutics Ltd's market capitalization is $1.16M as of September 17, 2026 at 1:30 AM IST.

  4. Scinai Immunotherapeutics Ltd's price-to-earnings (P/E) ratio is 0.06 as of September 16, 2026.

  5. Scinai Immunotherapeutics Ltd's price-to-book (P/B) ratio is 0.18 as of September 16, 2026.

  6. Yes, You can buy Scinai Immunotherapeutics Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Scinai Immunotherapeutics Ltd shares in three steps: 1. Search Scinai Immunotherapeutics Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Scinai Immunotherapeutics Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Scinai Immunotherapeutics Ltd (SCNI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.5963 shares at the current price of $1.51.

Loading...